Tadalafil is currently approved in at least 90 countries as an oral treatment for erectile dysfunction (ED). It is marketed throughout the world as Cialis1 (pronounced ‘‘See-AL-is’’). In Saudi Arabia, tadalafil is marketed as both Cialis1 and Snafi1. Tadalafil is an inhibitor of PDE5. After entering smooth muscle cells in arteries within the corpus cavernosum of the penis, tadalafil competitively inhibits PDE5, and prevents the inactivation of the intracellular messenger cGMP. Consequently, by inhibiting PDE5 in the corpus cavernosum, tadalafil prolongs the action of cGMP, facilitating the erectile response to sexual stimulation.
No comments:
Post a Comment